Aurobindo Pharma Ltd announced on Thursday it would make US-based COVAXX’s Covid-19 vaccine candidate for distribution in India and to the United Nations Children’s Fund (UNICEF) under a licensing deal.
The Indian drugmaker also has non-exclusive rights to sell the vaccine, currently undergoing an early-stage trial, in certain other emerging markets, the Indian pharma major said in an exchange filing.
COVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the United States.
The companies said the shot uses normal refrigeration which will make it easier to handle for developing countries.
Aurobindo said it could currently produce 220 million doses, but is ramping up its facilities to reach a capacity of nearly 480 million by June 2021.
The Indian authorities are likely to approve the AstraZeneca-Oxford vaccine for emergency use by next week.
India, the world’s biggest vaccine producing country, is also considering emergency use authorization applications for vaccines made by Pfizer and local company Bharat Biotech.
COVAXX claims it has already received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador..
Protest demonstrations broke out across different areas of Pakistan-occupied Gilgit-Baltistan after Friday prayers, with thousands…
Jamil Maqsood, the President of the Foreign Affairs Committee of the United Kashmir People's National…
The 6th meeting of the ASEAN-India Trade in Goods Agreement (AITIGA) Joint Committee concluded in…
The US Department of Homeland Security (DHS), on behalf of the Forced Labor Enforcement Task…
A delegation from the Tibetan Parliament-in-Exile (TPiE), led by Speaker Khenpo Sonam Tenphel and accompanied…
On the sidelines of the 2nd India-CARICOM Summit, leaders of the member countries witnessed a…